Sparsentan for children with protein leaking kidney diseases
Treatments studied
Part of Blood & lymphatic, Genetic & congenital, Heart & circulation, Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This Phase 2 study tests sparsentan in children with certain kidney diseases that cause high amounts of protein in the urine. It aims to see if the medicine can reduce kidney damage signals and protein leakage compared with standard care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your parent/guardian) can give consent/assent and follow study visits
- Kidney filtering test (eGFR) must be 30 or higher at screening
- Blood pressure on screening must be in the normal range for your age/size
- Your urine protein-to-creatinine ratio (UP/C) must be high enough (varies by diagnosis group)
- You must have one of the study’s specific kidney diagnoses, often confirmed by biopsy or genetics
- You must not have certain exclusions like recent major immune-suppressing medicine changes or pregnancy
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a medical device (the Liposorber LA-15) in children with focal segmental glomerulosclerosis (FSGS), a kidney condition that can cause heavy protein loss in the urine. It may help by improving disease control when standard treatments have not worked, were hard to tolerate, or can’t be used.
This Phase 2 trial studies whether sparsentan is safe and can slow down kidney damage in adults with IgA nephropathy (IgAN). Participants may receive sparsentan to improve kidney-related measures such as protein in the urine.
This trial tests an experimental medicine called atrasentan for children aged 2 to under 18 with IgA nephropathy, a kidney disease. The study aims to see if the drug can help protect kidney function and reduce protein in the urine, with fewer side effects than current treatments.
This study tests three experimental drugs (frexalimab, brivekimig, and rilzabrutinib) for people ages 16 to 75 with a type of kidney disease called primary FSGS or minimal change disease. The goal is to see if these drugs can reduce protein in your urine and help protect your kidneys.
This trial tests if a new medicine called BI 764198 can help people with a kidney condition called FSGS. It looks at whether the drug can reduce protein in the urine and protect kidney function.
This study is for children (and some newly diagnosed patients) who have nephrotic syndrome—kidneys leaking a lot of protein. It aims to better understand the kidney condition (sometimes using biopsy) and support future care decisions.
Hear when a new Focal Segmental Glomerulosclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.